<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Asthma Allergy</journal-id><journal-id journal-id-type="iso-abbrev">J Asthma Allergy</journal-id><journal-id journal-id-type="publisher-id">JAA</journal-id><journal-id journal-id-type="pmc">jaa</journal-id><journal-title-group><journal-title>Journal of Asthma and Allergy</journal-title></journal-title-group><issn pub-type="epub">1178-6965</issn><publisher><publisher-name>Dove</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">32021308</article-id><article-id pub-id-type="pmc">6954838</article-id><article-id pub-id-type="publisher-id">200917</article-id><article-id pub-id-type="doi">10.2147/JAA.S200917</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Clinical Utility of Rush Venom Immunotherapy: Current Status</article-title><alt-title alt-title-type="running-authors">Gruzelle et al</alt-title><alt-title alt-title-type="running-title">Gruzelle et al</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-7024-2118</contrib-id><name><surname>Gruzelle</surname><given-names>Vianney</given-names></name><xref ref-type="aff" rid="AFF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Mailhol</surname><given-names>Claire</given-names></name><xref ref-type="aff" rid="AFF0002">2</xref><xref ref-type="aff" rid="AFF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Waters</surname><given-names>David W</given-names></name><xref ref-type="aff" rid="AFF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>Guilleminault</surname><given-names>Laurent</given-names></name><xref ref-type="corresp" rid="AN0001"/><xref ref-type="aff" rid="AFF0002">2</xref><xref ref-type="aff" rid="AFF0004">4</xref></contrib><aff id="AFF0001"><label>1</label><institution>Department of Paediatric Pneumology and Allergology, University Hospital Centre of Toulouse</institution>, <addr-line>Toulouse</addr-line>, <country>France</country></aff><aff id="AFF0002"><label>2</label><institution>Department of Respiratory Medicine and Allergic Diseases, University Hospital Centre of Toulouse</institution>, <addr-line>Toulouse</addr-line>, <country>France</country></aff><aff id="AFF0003"><label>3</label><institution>Mastocytosis Reference Centre and Dermatology Department, University Hospital Centre of Toulouse</institution>, <addr-line>Toulouse</addr-line>, <country>France</country></aff><aff id="AFF0004"><label>4</label><institution>Center for Pathophysiology Toulouse Purpan, INSERM U1043, CNRS UMR 5282, Toulouse III University</institution>, <addr-line>Toulouse</addr-line>, <country>France</country></aff></contrib-group><author-notes><corresp id="AN0001">Correspondence: Laurent Guilleminault <institution>Department of Respiratory Medicine and Allergic Diseases H&#x000f4;pital Larrey</institution>, <addr-line>24 Chemin De Pouvourville</addr-line>, <addr-line>Toulouse</addr-line><addr-line>TSA 30030</addr-line>, <country>France</country><phone>Tel +335 67 77 18 50</phone><fax>Fax +335 67 77 14 72</fax> Email guilleminault.l@chu-toulouse.frww</corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>13</volume><fpage>1</fpage><lpage>10</lpage><history><date date-type="received"><day>19</day><month>10</month><year>2019</year></date><date date-type="accepted"><day>03</day><month>12</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Gruzelle et al.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Gruzelle et al.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution &#x02013; Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link>).</license-p></license></permissions><abstract><title>Abstract</title><p>Hymenoptera venom allergy (HVA) is the leading cause of anaphylactic reactions in adults and the second most common cause in children. Venom immunotherapy (VIT) is used to elicit an immune tolerance against hymenoptera venom in allergic patients and is based on the administration of purified venom extracts regularly for defined periods. The protocols of administration include 2 phases: an up-dosing phase that incrementally reaches the final dose resulting in a protective effect, and a maintenance phase in order to obtain the sustained effect. The goal of this review is to detail the efficacy and the safety of the up-dosing phase also named rush. Pathophysiological mechanisms, indications of VIT and technical aspects of up-dosing protocol are also covered.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>hymenoptera</kwd><kwd>allergy</kwd><kwd>immunotherapy</kwd></kwd-group><counts><fig-count count="1"/><table-count count="3"/><ref-count count="92"/><page-count count="10"/></counts></article-meta></front><body><sec sec-type="intro" id="S0001"><title>Introduction</title><p>Hymenoptera venom allergy (HVA) is the leading cause of anaphylactic reactions in adults.<xref rid="CIT0001" ref-type="bibr">1</xref> In children, it is acknowledged as the second most common cause, after food-related anaphylaxis.<xref rid="CIT0002" ref-type="bibr">2</xref> Such reactions are primarily due to stings by honeybees (<italic>Apis</italic>) and social wasps (<italic>Vespula vulgaris, Vespula germanica</italic>, and <italic>Polistes dominula</italic>, in particular). Insect stings by hymenoptera species are frequent with 56.6% to 94.5% of the general population stung at least once in their lifetime.<xref rid="CIT0003" ref-type="bibr">3</xref> Insect stings also affect young children, in an Irish prospective longitudinal study, 6.8% of children had been stung by the age of 2 years, and 21.9% had been stung by the age of 5 years.<xref rid="CIT0004" ref-type="bibr">4</xref></p><p>Sensitization to hymenoptera venom (HV) (defined by the positivity of skin prick-tests and/or specific IgE) is widely observed in the general population. The prevalence ranges from 27% to 40% of adults, and up to 50% of children.<xref rid="CIT0005" ref-type="bibr">5</xref> The prevalence of large local reactions (LLR), usually defined as swelling exceeding 10 cm of diameter that lasts &#x0003e;24 hrs, varies considerably from one study to another due to a non-uniform definition of LLR, different methodology of surveys, and different populations surveyed. In the general population, LLR ranges from 2.4% to 26.4%,<xref rid="CIT0006" ref-type="bibr">6</xref> in children a prevalence of 19% has been reported.<xref rid="CIT0007" ref-type="bibr">7</xref> In beekeepers, a high-risk group, prevalence ranges from 31% to 38%.<xref rid="CIT0008" ref-type="bibr">8</xref>,<xref rid="CIT0009" ref-type="bibr">9</xref> Currently, the risk of evolution of LLR to a systemic sting reactions (SSR) after re-sting is considered low, ranging from 5% to 15% in adults, and 2% to 4% in children.<xref rid="CIT0010" ref-type="bibr">10</xref>&#x02013;<xref rid="CIT0012" ref-type="bibr">12</xref> The rate of self-reported SSR in European studies ranges from 0.3% to 7.5% in adults of the general population.<xref rid="CIT0013" ref-type="bibr">13</xref> There is less reported SSR in children, rates range from 0.15% to 3.4%.<xref rid="CIT0013" ref-type="bibr">13</xref>&#x02013;<xref rid="CIT0015" ref-type="bibr">15</xref> Systemic sting reactions can be life threatening, with an estimated death rate of 0.03 to 0.48/1,000,000 inhabitants per year.<xref rid="CIT0003" ref-type="bibr">3</xref></p></sec><sec id="S0002"><title>History of Venom Immunotherapy</title><p>Reports of HVA can be found in the annals of history, the description of an anaphylactic response by Pharaoh Menes (2600 BC) to a wasp sting is thought to be the first documented anaphylactic death to HV.<xref rid="CIT0016" ref-type="bibr">16</xref> For centuries the management of HVA was rudimentary, with no noticeable progress for millennia. Detailed descriptions of HV stings started to appear in publications of the eighteenth and nineteenth century, describing what is now referred to as anaphylaxis.<xref rid="CIT0017" ref-type="bibr">17</xref></p><p>The first notable date regarding therapy was in 1925, when Dr Braun reported the effective use of immunotherapy in a bee allergic patient. In the report, Dr Braun described snipping off the posterior 1/8 inch of the Bee&#x02019;s body and grinding it up, extracting it in saline, and filtering the solution, demonstrating a positive skin test response and then using the same material to perform immunotherapy. In the following 40 years, a plethora of publication reinforced the efficacy of whole-body extract (WBE) for immunotherapy to Hymenoptera.<xref rid="CIT0018" ref-type="bibr">18</xref></p><p>In the 1970s, a second revolution took place, with the first purified venoms for desensitization. A publication from 1974 reports a successful case of immunotherapy using purified bee venom to treat a 4-year-old child with HVA.<xref rid="CIT0019" ref-type="bibr">19</xref>&#x02013;<xref rid="CIT0021" ref-type="bibr">21</xref></p></sec><sec id="S0003"><title>Pathophysiological Mechanism of Venom Immunotherapy</title><p>Initial sensitization to HV involves priming of allergen-specific T helper type 2 (Th2) cells resulting in the production of interlukin-4 (IL-4) and IL-13, and also CD40 ligand signaling. This cytokine signaling and ligand binding drives immunoglobulin-E (IgE) production by B cells.<xref rid="CIT0022" ref-type="bibr">22</xref> The resulting IgE binds mast cells and basophils via high-affinity Fc&#x003b5;RI receptors expressed on their surface.<xref rid="CIT0023" ref-type="bibr">23</xref> Upon subsequent HV exposure, antigen mediated IgE/Fc&#x003b5;RI crosslinking on the surface of sensitized cells triggers the release of pre-formed mediators contained in cytoplasmic granules, such as histamine, resulting in the development of a type I hypersensitivity reaction.<xref rid="CIT0024" ref-type="bibr">24</xref>&#x02013;<xref rid="CIT0026" ref-type="bibr">26</xref></p><p>The goal of venom immunotherapy (VIT) is to elicit a healthy immune response in HV allergic patients. Acquired tolerance is characterized by several mechanisms including changes to allergen-specific T and B cell responses and higher mast cell and basophil activation thresholds.<xref rid="CIT0027" ref-type="bibr">27</xref>,<xref rid="CIT0028" ref-type="bibr">28</xref> The early response to VIT is characterized by desensitization and subsequent decreased mediator release from mast cells and basophils.<xref rid="CIT0028" ref-type="bibr">28</xref>&#x02013;<xref rid="CIT0030" ref-type="bibr">30</xref> The rapid up-regulation of the histamine type 2 receptor, which has a suppressive effect on Fc&#x003b5;RI-mediated activation and degranulation, has been proposed to contribute to early desensitization,<xref rid="CIT0031" ref-type="bibr">31</xref> as have changes in Fc&#x003b5;RI expression;<xref rid="CIT0032" ref-type="bibr">32</xref> however, underlying mechanisms need to be further elucidated in order to better explain early desensitization events.</p><p>As allergen dosing increases, the next key event in the development of a healthy immune response is a change in T cell subset ratios.<xref rid="CIT0033" ref-type="bibr">33</xref> Research into beekeepers has shown that continuous exposure to high doses of HV suppresses allergen-specific T cell subsets and drives the switch towards IL-10 and Transforming growth factor beta (TGF&#x003b2;) secreting regulatory T cells (Tregs).<xref rid="CIT0031" ref-type="bibr">31</xref> These soluble mediators are key regulators of immunological processes in peripheral tolerance to allergens.<xref rid="CIT0034" ref-type="bibr">34</xref> Interluken-10 and TGF- &#x003b2; drive the switch in B cell antibody (Ab) production away from IgE towards the non-inflammatory isotypes IgA and IgG.<xref rid="CIT0035" ref-type="bibr">35</xref>,<xref rid="CIT0036" ref-type="bibr">36</xref> This switch in Ab production from IgE to IgA to IgG<sub>4</sub> is a key feature of long-term tolerance. Immunoglobulin-G<sub>4</sub> competes with IgE for allergen, blocking allergen-IgE complexes to prevent the degranulation of mast cells and basophils.<xref rid="CIT0037" ref-type="bibr">37</xref> Interlukin-10 also plays a direct role in inhibiting mast cell degranulation through signaling inhibition and also reducing Fc&#x003b5;RI expression and function<xref rid="CIT0038" ref-type="bibr">38</xref> (<xref rid="F0001" ref-type="fig">Figure 1</xref>).<fig id="F0001" fig-type="figure" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Mechanisms of immunotherapy. The switch from allergen-specific Th2 cells to Tregs is a key event during venom immunotherapy. Tregs secrete IL-10 and TGF&#x003b2;; these mediators suppress the degranulation of mast cells and basophils and reduce Fc&#x003b5;RI expression and function. IL-10 and TGF&#x003b2; also inhibit IgE production by B cells and drive the switch to the non-inflammatory isotypes IgA and IgG.</p></caption><graphic content-type="print-only" xlink:href="JAA-13-1-g0001"/></fig></p></sec><sec id="S0004"><title>Indications of VIT</title><p>Reactions following hymenoptera stings include physiological local reactions, related to the composition of venoms (histamine, serotonin, bradykinin, etc.), and allergic reactions. The latter can be divided into LLR at the sting site, which are the most common manifestation of HVA, and systemic reactions, ranging from isolated cutaneous reaction (e.g., urticaria) to SSR, which are the most severe (Classifications of reactions are detailed in <xref rid="T0001" ref-type="table">Table 1</xref>).<table-wrap id="T0001" orientation="portrait" position="float"><label>Table 1</label><caption><p>Definitions and VIT Indications for Each Type of Reaction</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Type of Reaction</th><th rowspan="1" colspan="1">Definition</th><th rowspan="1" colspan="1">VIT Indication</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Local reaction</td><td rowspan="1" colspan="1">Inflammatory reaction &#x0003c;10 cm of diameter.</td><td rowspan="1" colspan="1">No</td></tr><tr><td rowspan="1" colspan="1">LLR</td><td rowspan="1" colspan="1">Swelling exceeding 10 cm of diameter, that lasts &#x0003e;24 hrs.</td><td rowspan="1" colspan="1">To be discussed with the context and allergic tests</td></tr><tr><td rowspan="1" colspan="1">Moderate systemic reaction</td><td rowspan="1" colspan="1">Generalized skin symptoms (including flushing, urticaria, and angioedema).</td><td rowspan="1" colspan="1">Possibly, in adult, if impaired quality of life or risk factors associated.</td></tr><tr><td rowspan="1" colspan="1">SSR</td><td rowspan="1" colspan="1">Anaphylaxis, or shock and loss of consciousness, or even cardiac or respiratory arrest.</td><td rowspan="1" colspan="1">Yes</td></tr><tr><td rowspan="1" colspan="1">No sensitization</td><td rowspan="1" colspan="1">Type I allergic reaction without any sensitization highlighted.</td><td rowspan="1" colspan="1">No</td></tr><tr><td rowspan="1" colspan="1">Other situations</td><td rowspan="1" colspan="1">Unusual reactions (not type I immediate reactions) such as thrombocytopenic purpura and vasculitis, rhabdomyolysis, or renal failure after multiple stings</td><td rowspan="1" colspan="1">No</td></tr></tbody></table></table-wrap>
</p><p>Venom immunotherapy is indicated in children and adults following a SSR, exceeding generalized skin symptoms, with a documented sensitization to the venom of the culprit insect via skin prick tests and/or specific serum IgE tests and/or the basophil activation test.<xref rid="CIT0039" ref-type="bibr">39</xref>&#x02013;<xref rid="CIT0043" ref-type="bibr">43</xref> Concerning moderate SSR (i.e., SSR confined to generalized skin symptoms), VIT is recommended in adult patients if the quality of life is impaired.<xref rid="CIT0040" ref-type="bibr">40</xref>,<xref rid="CIT0044" ref-type="bibr">44</xref>,<xref rid="CIT0045" ref-type="bibr">45</xref> When faced with this clinical situation it is also necessary to identify risk factors for relapse, and factors aggravating the severity of a possible recurrence (e.g., mastocytosis).</p><p>Generally, patients with repeated LLR are reported as having minimal risk of progressing to SSR. VIT is not typically recommended for these patients.<xref rid="CIT0046" ref-type="bibr">46</xref>,<xref rid="CIT0047" ref-type="bibr">47</xref> Nevertheless, a recent prospective study indicates a risk of 24% SSR in adults and children after an initial LLR.<xref rid="CIT0048" ref-type="bibr">48</xref> The risk of SSR was reported to be higher in cases of skin test reactivity to <italic>Apis mellifera</italic> or <italic>Vespula</italic> species (OR 2.1 and 3.8, respectively), if positive at 0.001 &#x000b5;g/mL concentration (OR 13.4 and 16.5, respectively). For the authors, an accurate diagnostic workup may be considered in LLR, particularly skin tests. If skin tests are positive at low dilutions, VIT may be performed because of a high risk (24%) of developing SSR if re-sting occurs particularly in at-risk population. However, more studies are warranted to clarify the place of VIT in LLR.</p><p>Scenarios when VIT should not be considered include: the lack of sensitization to insect venom during skin prick tests or the absence of specific IgE. In patients that are sensitized to insect venom but have not experienced a SSR, VIT should not be considered. Additionally, VIT should also not be considered in the context of unusual reactions that are not attributed to type I hypersensitivity reactions such as thrombocytopenic purpura and vasculitis, rhabdomyolysis, or renal failure after multiple stings<xref rid="CIT0003" ref-type="bibr">3</xref> (see <xref rid="T0001" ref-type="table">Table 1</xref>).</p><p>Typically, the diagnosis of HVA has been based on skin tests and specific IgE to WBE. However, recently component-resolved diagnosis (CRD) has been developed in which venom allergen proteins, instead of WBE, are now used to characterize sensitization in patients.<xref rid="CIT0049" ref-type="bibr">49</xref> Venom allergen proteins are produced by genetic engineering using insect cells.<xref rid="CIT0050" ref-type="bibr">50</xref> The available CRD data on HV in clinical practice are presented in <xref rid="T0002" ref-type="table">Table 2</xref>. There are limited benefits of adding recombinant allergens to improve the detection of Hymenoptera venom-allergic patients.<xref rid="CIT0049" ref-type="bibr">49</xref> One of the most important disadvantages of WBE is the underrepresentation of allergens that are present in low abundance. This may lead to the failure to detect sensitization in some cases.<xref rid="CIT0051" ref-type="bibr">51</xref> Regarding the high amount of Api m 1 and Api m 4 in WBE, which represent together 62% of the dry weight, CRD does not improve detection rates. However, the use of WBE allergens in low abundance, such as Api m 3 or Api m 10, may lead to underdiagnosing the severity of venom allergy.<table-wrap id="T0002" orientation="portrait" position="float"><label>Table 2</label><caption><p>Available Component-Resolved Diagnosis of Venom Hymenptera in Clinical Practice</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Bee Venom Proteins</th><th rowspan="1" colspan="1">Vespula Venom Proteins</th><th rowspan="1" colspan="1">Polistes Venom Proteins</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Api m 1</td><td rowspan="1" colspan="1">Ves v 1</td><td rowspan="1" colspan="1">Pol d 1</td></tr><tr><td rowspan="1" colspan="1">Api m 3</td><td rowspan="1" colspan="1">Ves v 4</td><td rowspan="1" colspan="1">Pol d 5</td></tr><tr><td rowspan="1" colspan="1">Api m 4</td><td rowspan="1" colspan="1">Ves v 5</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Api m 6</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Api m 7</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Api m 8</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Api m 9</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Api m 10</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Api m 11</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></tbody></table></table-wrap>
</p></sec><sec id="S0005"><title>Venom Immunotherapy: Technical Aspects and Up-Dosing Protocols</title><p>Although early case studies carried out VIT using WBE, VIT is now practiced with industrially produced venom extracts with the specific allergen composition standardized. When the culprit hymenoptera has been identified and allergy diagnosis confirmed, venom extract can be administered, subcutaneously, following standardized protocols. These protocols always include 2 phases: an up-dosing phase that incrementally reaches the final dose resulting in a protective effect, and a maintenance phase in order to obtain the sustained effect.</p><p>This final dose may be reached within a few weeks to months (in outpatient clinics), days or hours (ultra-rush or cluster protocols including several injections a day) depending on the protocol. These protocols include administrated doses and cumulative doses (<xref rid="T0003" ref-type="table">Table 3</xref> describes some published administration protocols).<xref rid="CIT0052" ref-type="bibr">52</xref>&#x02013;<xref rid="CIT0057" ref-type="bibr">57</xref> In the published literature describing VIT protocols, clinical characteristics of the patients are disparate, and the number of patients is sometimes low. Considering its brevity and simplicity, Birnbaum&#x02019;s protocol is used as a reference in our department. The data in <xref rid="T0003" ref-type="table">Table 3</xref> may help to determine the most appropriate protocol for other teams to adopt. In case of toxicity or reaction to an ultra-rush protocol, our department utilizes a protocol with a slow administration among those presented in <xref rid="T0003" ref-type="table">Table 3</xref>.<table-wrap id="T0003" orientation="portrait" position="float"><label>Table 3</label><caption><p>Examples of Injection Schedule Published for VIT</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Birnbaum<xref rid="CIT0052" ref-type="bibr">52</xref></th><th rowspan="1" colspan="1">Laurent<xref rid="CIT0053" ref-type="bibr">53</xref></th><th rowspan="1" colspan="1">Sturm<xref rid="CIT0054" ref-type="bibr">54</xref></th><th rowspan="1" colspan="1">Vander Zwan<xref rid="CIT0055" ref-type="bibr">55</xref></th><th rowspan="1" colspan="1">Roll<xref rid="CIT0056" ref-type="bibr">56</xref></th><th rowspan="1" colspan="1">Malling<xref rid="CIT0057" ref-type="bibr">57</xref></th></tr><tr><th rowspan="1" colspan="1">Day</th><th rowspan="1" colspan="1">Time (min)</th><th rowspan="1" colspan="1">Dose (&#x000b5;g)</th><th rowspan="1" colspan="1">Dose (&#x000b5;g)</th><th rowspan="1" colspan="1">Dose (&#x000b5;g)</th><th rowspan="1" colspan="1">Dose (&#x000b5;g)</th><th rowspan="1" colspan="1">Dose (&#x000b5;g)</th><th rowspan="1" colspan="1">Dose (&#x000b5;g)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.1</td><td rowspan="1" colspan="1">0.001</td><td rowspan="1" colspan="1">0.001</td><td rowspan="1" colspan="1">*</td><td rowspan="1" colspan="1">0.1</td><td rowspan="1" colspan="1">0.02</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0.002</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0.1</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">60</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">0.004</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">0.2</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">90</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">0.008</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">0.6</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">120</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">0.1</td><td rowspan="1" colspan="1">60</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">150</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">0.02</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">180</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.04</td><td rowspan="1" colspan="1">02</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">210</td><td rowspan="1" colspan="1">40</td><td rowspan="1" colspan="1">0.08</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">50</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">240</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.1</td><td rowspan="1" colspan="1">0.4</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">270</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.2</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">300</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.4</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">330</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.8</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">360</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">390</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0.8</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">60</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">90</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">120</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">180</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">240</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">270</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">360</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">420</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">60</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">120</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">180</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">40</td><td rowspan="1" colspan="1">40</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">240</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">60</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">420</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">50</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1">80</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">60</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1.6</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">60</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">90</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">4</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">120</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">8</td></tr><tr><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1">8</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">12</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">60</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">16</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">90</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">20</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">120</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">40</td></tr><tr><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">50</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">50</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">40</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">80</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">60</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">120</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">90</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">160</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">120</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">200</td></tr><tr><td rowspan="1" colspan="1">45</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold> *The initial dose of venom was a factor of 10 40- measured every half hour. The threshold for the venom in the skin &#x02013; that is, amount of venom that provoked a reaction &#x02013; was estimated, and the initial dose of venom was a factor 10 below the 30 &#x02212;6 threshold. The venom was injected subcutaneously in both upper legs. The amount of venom was increased 10-fold up to 1 mcg.</p></fn></table-wrap-foot></table-wrap>
</p><p>The data suggest that sustained tolerance is achieved more effectively using long-way protocols compared to ultra-rush protocols.<xref rid="CIT0039" ref-type="bibr">39</xref></p></sec><sec id="S0006"><title>At-Risk Populations</title><p>Recent data suggest that 5 to 15% of anaphylactic reactions to venom hymenopthera show signs of potential mastocytosis. Systemic mastocytosis may be evoked and diagnosed during hymenoptera allergy care by serum tryptase dosage and cutaneous examination.<xref rid="CIT0058" ref-type="bibr">58</xref> These patients often show a very low specific IgE level. Mastocytosis and serum tryptase level over 20 &#x000b5;g/L are associated with higher risk of adverse events in VIT in vespid allergy.<xref rid="CIT0039" ref-type="bibr">39</xref> The REMA score can help to identify, with a 90% predictive value, patients with a clonal mast cell disorder when at least 2 criteria are met.<xref rid="CIT0059" ref-type="bibr">59</xref> Efficacy is potentially lower with relapses after stopping VIT. Life-long therapy is recommended in patients with mastocytosis. Up-dosing is not necessary except in adverse events during VIT. Ultra-rush protocols seem to be well tolerated in patients with mastocytosis<xref rid="CIT0060" ref-type="bibr">60</xref> and VIT is considered safe.<xref rid="CIT0039" ref-type="bibr">39</xref></p><p>In beekeepers, treatment with bee venom is the most important risk factor for systemic adverse events with VIT. Upgrading maintenance dose and long-life treatment should be considered in the bee-keeping population.<xref rid="CIT0039" ref-type="bibr">39</xref></p><p>Regarding current guidelines, VIT should not be initiated during pregnancy; however, if ongoing VIT is well tolerated this may be continued.<xref rid="CIT0039" ref-type="bibr">39</xref> In children below 5 years of age, VIT should only be considered in the event of a SSR and when the child is likely to be co-operative. VIT is not recommended in patients with active multi-system autoimmune disorders. Nevertheless, VIT is recommended in patients with organ-specific autoimmune disorders and patients with cardiovascular disease providing that the underlying disease is stabilized, and in high-risk venom-allergic patients with malignant disease as long as the disease is stable or in remission.</p></sec><sec id="S0007"><title>Effectiveness of Venom Immunotherapy</title><p>The main goal of VIT is to prevent a relapse of systemic reaction in a context of hymenoptera re-sting. This treatment is mainly considered as a preventive treatment. Evaluation of efficacy can be challenging especially when the patient undergoing VIT has not been exposed to HV since the last clinical visit.</p><p>Two meta-analysis studies have evaluated the effect of VIT on the risk of systemic reaction to a sting. Meta-analysis conducted by the Cochrane database pooled the results from 6 studies (392 patients).<xref rid="CIT0041" ref-type="bibr">41</xref> A subsequent systemic allergic reaction to a sting was observed in 3 out of 113 (2.7%) participants treated with VIT compared to 37 out of 93 (39.8%) untreated patients. The risk ratio was established at 0.10 [95% confidence interval (CI) 0.03 to 0.28]. Suggesting the risk of a systemic reaction to a sting decreases by 90% with VIT. In a more recent meta-analysis, 17 studies were retained for the final analysis.<xref rid="CIT0040" ref-type="bibr">40</xref> The authors concluded that VIT was beneficial with a substantial reduction of the risk of subsequent SSR (OR=0.08, 95% CI 0.03 to 0.26).</p><p>Venom immunotherapy is recognized as the only treatment that can potentially prevent further SSR. Its effectiveness ranges from 77% to 84% of patients treated with honeybee venom, and in 91&#x02013;96% of patients receiving vespid venom.<xref rid="CIT0061" ref-type="bibr">61</xref>,<xref rid="CIT0062" ref-type="bibr">62</xref> The difference between honeybee and vespid has not been fully elucidated. It has been speculated that the amount of venom delivered by a honeybee sting is more important and some patients allergic to honeybee venom are sensitized to protein present in a low amount of immunotherapy solution.<xref rid="CIT0063" ref-type="bibr">63</xref>,<xref rid="CIT0064" ref-type="bibr">64</xref></p><p>In the European Academy of Allergy and Clinical Immunology (EAACI) guidelines, beyond the benefit of VIT in preventing SSR, the authors highlight VIT also improves quality of life.<xref rid="CIT0039" ref-type="bibr">39</xref> In patients with an allergy to HV, 80% declared a significant improvement in health-related quality of life after a sting challenge test.<xref rid="CIT0065" ref-type="bibr">65</xref> Disease-specific quality of life was also shown to be improved in a meta-analysis study with a risk difference of 1.41 (95% CI 1.04&#x02013;1.79).<xref rid="CIT0040" ref-type="bibr">40</xref></p><p>These data take into account the whole treatment with immunotherapy and do not focus on the build-up phase. As explained above, several schedules are used in the build-up phase to reach the maintained dose. The efficacy of the build-up phase in terms of efficacy has not been extensively studied. After rush immunotherapy, a decrease in skin-test sensitivity has been observed.<xref rid="CIT0066" ref-type="bibr">66</xref> However, no study has yet identified a relevant difference in skin test reactivity between tolerant subjects and patients with relapses.<xref rid="CIT0067" ref-type="bibr">67</xref>,<xref rid="CIT0068" ref-type="bibr">68</xref> Sting challenges are considered the gold standard for the assessment of VIT efficacy, but the challenges are feasible only in specialized centers. Only one study to date had focused on the efficacy of rush VIT, the authors report interesting data on response to sting challenge after the build-up phase.<xref rid="CIT0069" ref-type="bibr">69</xref> Bee venom-allergic patients who underwent conventional or rush VIT were challenged with a live bee sting within 1 week after reaching the 100 &#x000b5;g maintenance dose. Among the 107 patients, 79 (73.8%) agreed to be challenge, 70 (88.6%) tolerated the challenge with no reaction. Only 4 (5.1%) patients developed a transient rash. Five (6.3%) presented a mild-to-moderate systemic reaction and 4 were given an increased dose of VIT (200&#x02013;250&#x000b5;g) and tolerate further challenges.</p><p>To our knowledge, the effectiveness of the different schedules used in the build-up phase have never been compared. Studies have only focused on the safety of VIT schedules.</p></sec><sec id="S0008"><title>Safety of Venom Immunotherapy</title><p>The most important objective of the build-up phase is to reach the maintenance dose with no reactions. As described above, several schedules can be employed in the build-up phase. The safety of the build-up phase is high as the maintenance dose is reached in 96.6% of patients with a rush protocol<xref rid="CIT0070" ref-type="bibr">70</xref> and 97.5% of patients with an ultra-rush protocol.<xref rid="CIT0056" ref-type="bibr">56</xref> A systemic reaction was shown to occur in patients receiving a 3-day protocol with a frequency ranging from 10.9% to 29.6%.<xref rid="CIT0070" ref-type="bibr">70</xref>&#x02013;<xref rid="CIT0072" ref-type="bibr">72</xref> A local reaction has been described in 42.3% of patients receiving a 3-day protocol. Regarding the ultra-rush protocol, systemic reactions range from 7% to 22%.<xref rid="CIT0056" ref-type="bibr">56</xref>,<xref rid="CIT0073" ref-type="bibr">73</xref>&#x02013;<xref rid="CIT0075" ref-type="bibr">75</xref> The vast majority of systemic reactions are mild and do not need medication.<xref rid="CIT0076" ref-type="bibr">76</xref> However, life-threatening anaphylaxis and fatal anaphylaxis have been described,<xref rid="CIT0077" ref-type="bibr">77</xref> and the build-up phase should be managed by trained health care professionals able to start resuscitation if needed. Uncontrolled asthma, a prior history of SRs, administration of SCIT injections during peak pollen season, and delay in administration of epinephrine are recognized factors of fatal reaction to VIT.<xref rid="CIT0078" ref-type="bibr">78</xref>,<xref rid="CIT0079" ref-type="bibr">79</xref> Reactions to immunotherapy are not restricted to the build-up phase and may appear during the maintenance phase. An increase in observed reactions during the build-up phase compared to the maintenance phase has been described (1.5% vs 2.4%).<xref rid="CIT0072" ref-type="bibr">72</xref> However, this is still debated and some authors described an increased risk of fatal reactions during the maintenance phase.<xref rid="CIT0078" ref-type="bibr">78</xref></p><p>Potential adverse reactions from VIT are difficult to predict. In a prospective study carried out on 680 patients, index sting reaction grade III or IV, and female sex were not identified as risk factors of a reaction needing an emergency intervention.<xref rid="CIT0080" ref-type="bibr">80</xref> Bee VIT clearly increases the risk of reactions compared to vespid venom.<xref rid="CIT0070" ref-type="bibr">70</xref>,<xref rid="CIT0074" ref-type="bibr">74</xref>,<xref rid="CIT0080" ref-type="bibr">80</xref> Before VIT, measurement of baseline serum tryptase concentration should be used to identify patients with a high risk for side effects. Moreover, mastocytosis is a significant determinant for VIT failure.<xref rid="CIT0062" ref-type="bibr">62</xref> Conventional protocols are less likely to result in a reaction needing an emergency intervention<xref rid="CIT0080" ref-type="bibr">80</xref> compared to ultra-rush protocols which have been shown to increase the frequency of adverse reactions.<xref rid="CIT0080" ref-type="bibr">80</xref> It should be acknowledged that several studies have suggested that an ultra-rush protocol may be associated with less adverse reactions compared to rush or conventional protocols; however, the cumulative effect was not comparable between the schedules.<xref rid="CIT0052" ref-type="bibr">52</xref>,<xref rid="CIT0081" ref-type="bibr">81</xref></p><p>Beta-blockers had been considered to increase the risk of a systemic reaction during VIT particularly in patients with cardiovascular diseases.<xref rid="CIT0082" ref-type="bibr">82</xref> However, two large studies,<xref rid="CIT0080" ref-type="bibr">80</xref>,<xref rid="CIT0083" ref-type="bibr">83</xref> and a position paper published by the EAACI<xref rid="CIT0084" ref-type="bibr">84</xref> suggest beta-blockers are no longer to be considered as contra-indicated in VIT. Although angiotensin conversion enzyme inhibitors (ACEI) were previously associated with systemic reactions during VIT, the EAACI has now recommended that ACEI therapy can be continued during VIT as long as the patient is informed about possible risks.<xref rid="CIT0039" ref-type="bibr">39</xref> Any use of anti-hypertensive drugs has been identified as a significant risk factor of systemic reactions to VIT.<xref rid="CIT0080" ref-type="bibr">80</xref> However, in a retrospective study that focused on patients with cardiovascular diseases, cardiovascular medication did not impair the safety and/or the efficacy of VIT.<xref rid="CIT0085" ref-type="bibr">85</xref> Surprisingly, reaction rates were lower in patients taking any kind of cardiovascular medication or an ACEI. Patients taking anti-hypertensive drugs should be evaluated carefully before starting VIT, based on an individual risk/benefit assessment.</p><p>Pre-treatment with antihistamines reduces large local reactions and systemic reactions and should be used in clinical practice 1 or 2 hrs before starting VIT.<xref rid="CIT0086" ref-type="bibr">86</xref> In rare cases, VIT is associated with severe systemic reactions with conventional protocols. Pre-treatment with omalizumab has been used in case reports and case series with interesting effects.<xref rid="CIT0087" ref-type="bibr">87</xref>&#x02013;<xref rid="CIT0089" ref-type="bibr">89</xref> In patients with severe systemic reactions to VIT, omalizumab was not associated with a reaction when administered concomitantly with VIT. The regimen of omalizumab administration varies between studies and so a typical regimen of administration cannot be referenced.</p></sec><sec id="S0009"><title>Maintenance Dosing and Long-Term Evaluation of Venom Immunotherapy</title><p>Once the maintenance dose has been reached, venom extract must be injected regularly in order to obtain long-term effects.</p><p>The maintenance dose is typically 100 &#x000b5;g of the culprit venom (equivalent to 2 honeybee stings or 5 wasp stings). Some specific cases require an increase to 200 &#x000b5;g: patients who experience anaphylaxis under ongoing VIT, beekeepers and other high-risk populations. Intervals of 4 to 6 weeks between injections are recommended in the EAACI guidelines: 4 weeks during the first year, 6 during the second year and 8 weeks between 3 and 5 years, intervals may be extended to 3 months however no effect has been demonstrated when intervals are extended to 6 months.</p><p>Venom immunotherapy duration of 3 years may be sufficient in most cases with mild reactions; however, 5 years of VIT are associated with more successful long-term effectiveness. The EAACI guidelines also recommend considering life-long treatment in patients that experience a severe initial systemic reaction or systemic adverse events during VIT. Honeybee venom-allergic patients with a high risk of stings, such as beekeepers should also carry out lifelong VIT to prevent relapse.</p><p>Effectiveness may reach a 97 to 98% protection with a better score in vespid VIT than in honeybee.<xref rid="CIT0039" ref-type="bibr">39</xref></p></sec><sec id="S0010"><title>Conclusion</title><p>Venom immunotherapy is effective for patients with HVA. It is the only causal and preventive treatment with respect to potential future sting reactions. Hymenoptera venom allergy indications are well codified. The build-up phase relies mainly on the ultra-rush protocol. Venom immunotherapy should be carried out for 3 to 5 years, or life-long in high-risk populations.</p></sec></body><back><sec id="S0011"><title>Author Contributions</title><p>All authors contributed to data analysis, drafting and revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.</p></sec><sec id="S0012" sec-type="COI-statement"><title>Disclosure</title><p>LG declares financial and non-financial support from ALK, during the conduct of this work. CM declares non-financial support from ALK. The authors report no other conflicts of interest in this work.</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1.</label><mixed-citation publication-type="journal"><string-name><surname>Worm</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Moneret&#x02010;Vautrin</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Scherer</surname>
<given-names>K</given-names></string-name>, et al. <article-title>First European data from the network of severe allergic reactions (NORA)</article-title>. <source><italic toggle="yes">Allergy</italic></source>. <year>2014</year>;<volume>69</volume>(<issue>10</issue>):<fpage>1397</fpage>&#x02013;<lpage>1404</lpage>. doi:<pub-id pub-id-type="doi">10.1111/all.12475</pub-id><pub-id pub-id-type="pmid">24989080</pub-id></mixed-citation></ref><ref id="CIT0002"><label>2.</label><mixed-citation publication-type="journal"><string-name><surname>Grabenhenrich</surname>
<given-names>LB</given-names></string-name>, <string-name><surname>D&#x000f6;lle</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Moneret-Vautrin</surname>
<given-names>A</given-names></string-name>, et al. <article-title>Anaphylaxis in children and adolescents: the European Anaphylaxis Registry</article-title>. <source><italic toggle="yes">J Allergy Clin Immunol</italic></source>. <year>2016</year>;<volume>137</volume>(<issue>4</issue>):<fpage>1128</fpage>&#x02013;<lpage>1137. e1121</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jaci.2015.11.015</pub-id><pub-id pub-id-type="pmid">26806049</pub-id></mixed-citation></ref><ref id="CIT0003"><label>3.</label><mixed-citation publication-type="journal"><string-name><surname>Antonicelli</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Bil&#x000f2;</surname>
<given-names>MB</given-names></string-name>, <string-name><surname>Bonifazi</surname>
<given-names>F</given-names></string-name>. <article-title>Epidemiology of Hymenoptera allergy</article-title>. <source><italic toggle="yes">Curr Opin Allergy Clin Immunol</italic></source>. <year>2002</year>;<volume>2</volume>(<issue>4</issue>):<fpage>341</fpage>&#x02013;<lpage>346</lpage>. doi:<pub-id pub-id-type="doi">10.1097/00130832-200208000-00008</pub-id><pub-id pub-id-type="pmid">12130949</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4.</label><mixed-citation publication-type="journal"><string-name><surname>Clifford</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Ni Chaoimh</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Stanley</surname>
<given-names>E</given-names></string-name>, <string-name><surname>O&#x02019;B Hourihane</surname>
<given-names>J</given-names></string-name>. <article-title>A longitudinal study of hymenoptera stings in preschool children</article-title>. <source><italic toggle="yes">Pediatr Allergy Immunol</italic></source>. <year>2019</year>;<volume>30</volume>(<issue>1</issue>):<fpage>93</fpage>&#x02013;<lpage>98</lpage>. doi:<pub-id pub-id-type="doi">10.1111/pai.2019.30.issue-1</pub-id><pub-id pub-id-type="pmid">30298641</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5.</label><mixed-citation publication-type="journal"><string-name><surname>Jakob</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Rafei-Shamsabadi</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Spillner</surname>
<given-names>E</given-names></string-name>, <string-name><surname>M&#x000fc;ller</surname>
<given-names>S</given-names></string-name>. <article-title>Diagnostics in Hymenoptera venom allergy: current concepts and developments with special focus on molecular allergy diagnostics</article-title>. <source><italic toggle="yes">Allergo J Int</italic></source>. <year>2017</year>;<volume>26</volume>(<issue>3</issue>):<fpage>93</fpage>&#x02013;<lpage>105</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s40629-017-0014-2</pub-id><pub-id pub-id-type="pmid">28503403</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6.</label><mixed-citation publication-type="journal"><string-name><surname>Bilo</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Bonifazi</surname>
<given-names>F</given-names></string-name>. <article-title>The natural history and epidemiology of insect venom allergy: clinical implications</article-title>. <source><italic toggle="yes">Clin Exp Allergy</italic></source>. <year>2009</year>;<volume>39</volume>(<issue>10</issue>):<fpage>1467</fpage>&#x02013;<lpage>1476</lpage>. doi:<pub-id pub-id-type="doi">10.1111/cea.2009.39.issue-10</pub-id><pub-id pub-id-type="pmid">19622088</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7.</label><mixed-citation publication-type="journal"><string-name><surname>Novembre</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Cianferoni</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Bernardini</surname>
<given-names>R</given-names></string-name>, et al. <article-title>Epidemiology of insect venom sensitivity in children and its correlation to clinical and atopic features</article-title>. <source><italic toggle="yes">Clin Exp Allergy</italic></source>. <year>1998</year>;<volume>28</volume>(<issue>7</issue>):<fpage>834</fpage>&#x02013;<lpage>838</lpage>. doi:<pub-id pub-id-type="doi">10.1046/j.1365-2222.1998.00313.x</pub-id><pub-id pub-id-type="pmid">9720817</pub-id></mixed-citation></ref><ref id="CIT0008"><label>8.</label><mixed-citation publication-type="journal"><string-name><surname>Garc&#x000ed;a-Robaina</surname>
<given-names>J</given-names></string-name>, <string-name><surname>V&#x000e1;zquez-Monchol&#x000ed;</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Fierro</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Bonnet-Moreno</surname>
<given-names>C</given-names></string-name>. <article-title>Epidemiology of allergic reactions in beekeepers: a lower prevalence in subjects with more than 5 years exposure</article-title>. <source><italic toggle="yes">Allergol Immunopathol</italic></source>. <year>1995</year>;<volume>23</volume>(<issue>3</issue>):<fpage>127</fpage>&#x02013;<lpage>132</lpage>.</mixed-citation></ref><ref id="CIT0009"><label>9.</label><mixed-citation publication-type="journal"><string-name><surname>Annila</surname>
<given-names>IT</given-names></string-name>, <string-name><surname>Karjalainen</surname>
<given-names>ES</given-names></string-name>, <string-name><surname>Annila</surname>
<given-names>PA</given-names></string-name>, <string-name><surname>Kuusisto</surname>
<given-names>PA</given-names></string-name>. <article-title>Bee and wasp sting reactions in current beekeepers</article-title>. <source><italic toggle="yes">Ann Allergy Asthma Immunol</italic></source>. <year>1996</year>;<volume>77</volume>(<issue>5</issue>):<fpage>423</fpage>&#x02013;<lpage>427</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1081-1206(10)63342-X</pub-id><pub-id pub-id-type="pmid">8933782</pub-id></mixed-citation></ref><ref id="CIT0010"><label>10.</label><mixed-citation publication-type="journal"><string-name><surname>Severino</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Bonadonna</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Passalacqua</surname>
<given-names>G</given-names></string-name>. <article-title>Large local reactions from stinging insects: from epidemiology to management</article-title>. <source><italic toggle="yes">Curr Opin Allergy Clin Immunol</italic></source>. <year>2009</year>;<volume>9</volume>(<issue>4</issue>):<fpage>334</fpage>&#x02013;<lpage>337</lpage>. doi:<pub-id pub-id-type="doi">10.1097/ACI.0b013e32832d0668</pub-id><pub-id pub-id-type="pmid">19458526</pub-id></mixed-citation></ref><ref id="CIT0011"><label>11.</label><mixed-citation publication-type="journal"><string-name><surname>Graft</surname>
<given-names>DF</given-names></string-name>, <string-name><surname>Schuberth</surname>
<given-names>KC</given-names></string-name>, <string-name><surname>Kagey-Sobotka</surname>
<given-names>A</given-names></string-name>, et al. <article-title>A prospective study of the natural history of large local reactions after Hymenoptera stings in children</article-title>. <source><italic toggle="yes">J Pediatr</italic></source>. <year>1984</year>;<volume>104</volume>(<issue>5</issue>):<fpage>664</fpage>&#x02013;<lpage>668</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0022-3476(84)80940-3</pub-id><pub-id pub-id-type="pmid">6716215</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12.</label><mixed-citation publication-type="journal"><string-name><surname>M&#x000fc;ller</surname>
<given-names>UR</given-names></string-name>. <article-title>Insect sting allergy: clinical picture, diagnosis and treatment</article-title>. <source><italic toggle="yes">Insect Sting Allergy</italic></source>. <year>1990</year>.</mixed-citation></ref><ref id="CIT0013"><label>13.</label><mixed-citation publication-type="journal"><string-name><surname>Bilo</surname>
<given-names>BM</given-names></string-name>, <string-name><surname>Bonifazi</surname>
<given-names>F</given-names></string-name>. <article-title>Epidemiology of insect-venom anaphylaxis</article-title>. <source><italic toggle="yes">Curr Opin Allergy Clin Immunol</italic></source>. <year>2008</year>;<volume>8</volume>(<issue>4</issue>):<fpage>330</fpage>&#x02013;<lpage>337</lpage>. doi:<pub-id pub-id-type="doi">10.1097/ACI.0b013e32830638c5</pub-id><pub-id pub-id-type="pmid">18596590</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14.</label><mixed-citation publication-type="journal"><string-name><surname>Bilo</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Rueff</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Mosbech</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Bonifazi</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Oude&#x02010;Elberink</surname>
<given-names>J</given-names></string-name>, <collab>Hypersensitivity EIGoIV</collab>. <article-title>Diagnosis of Hymenoptera venom allergy</article-title>. <source><italic toggle="yes">Allergy</italic></source>. <year>2005</year>;<volume>60</volume>(<issue>11</issue>):<fpage>1339</fpage>&#x02013;<lpage>1349</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1398-9995.2005.00963.x</pub-id><pub-id pub-id-type="pmid">16197464</pub-id></mixed-citation></ref><ref id="CIT0015"><label>15.</label><mixed-citation publication-type="journal"><string-name><surname>Jennings</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Duggan</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Perry</surname>
<given-names>IJ</given-names></string-name>, <string-name><surname>Hourihane</surname>
<given-names>JOB</given-names></string-name>. <article-title>Epidemiology of allergic reactions to hymenoptera stings in Irish school children</article-title>. <source><italic toggle="yes">Pediatr Allergy Immunol</italic></source>. <year>2010</year>;<volume>21</volume>(<issue>8</issue>):<fpage>1166</fpage>&#x02013;<lpage>1170</lpage>. doi:<pub-id pub-id-type="doi">10.1111/pai.2010.21.issue-8</pub-id><pub-id pub-id-type="pmid">20408970</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16.</label><mixed-citation publication-type="journal"><string-name><surname>Vetter</surname>
<given-names>RS</given-names></string-name>. <article-title>Wasp or hippopotamus?</article-title>
<source><italic toggle="yes">J Allergy Clin Immunol</italic></source>. <year>2000</year>;<volume>106</volume>(<issue>1</issue>):<fpage>196</fpage>. doi:<pub-id pub-id-type="doi">10.1067/mai.2000.106547</pub-id></mixed-citation></ref><ref id="CIT0017"><label>17.</label><mixed-citation publication-type="journal"><string-name><surname>Ring</surname>
<given-names>J</given-names></string-name>. <chapter-title>History of allergy in antiquity</chapter-title>
<italic>Chem Immunol Allergy</italic>&#x000a0;<year>2014</year>;<volume>100</volume>:<fpage>2&#x02013;14</fpage>.</mixed-citation></ref><ref id="CIT0018"><label>18.</label><mixed-citation publication-type="journal"><string-name><surname>Oppenheimer</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Golden</surname>
<given-names>DB</given-names></string-name>. <article-title>Hymenoptera venom immunotherapy: past, present, and future</article-title>. <source><italic toggle="yes">Ann Allergy Asthma Immunol</italic></source>. <year>2018</year>;<volume>121</volume>(<issue>3</issue>):<fpage>276</fpage>&#x02013;<lpage>277</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.anai.2018.06.006</pub-id><pub-id pub-id-type="pmid">29909053</pub-id></mixed-citation></ref><ref id="CIT0019"><label>19.</label><mixed-citation publication-type="journal"><string-name><surname>Lichtenstein</surname>
<given-names>LM</given-names></string-name>, <string-name><surname>Valentine</surname>
<given-names>MD</given-names></string-name>, <string-name><surname>Sobotka</surname>
<given-names>AK</given-names></string-name>. <article-title>A case for venom treatment in anaphylactic sensitivity to Hymenoptera sting</article-title>. <source><italic toggle="yes">N Engl J Med</italic></source>. <year>1974</year>;<volume>290</volume>(<issue>22</issue>):<fpage>1223</fpage>&#x02013;<lpage>1227</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJM197405302902204</pub-id><pub-id pub-id-type="pmid">4133096</pub-id></mixed-citation></ref><ref id="CIT0020"><label>20.</label><mixed-citation publication-type="journal"><string-name><surname>Galli</surname>
<given-names>SJ</given-names></string-name>. <article-title>Mary Hewitt Loveless, MD: the origin of venom immunotherapy</article-title>. <source><italic toggle="yes">Ann Allergy Asthma Immunol</italic></source>. <year>2018</year>;<volume>121</volume>(<issue>3</issue>):<fpage>268</fpage>&#x02013;<lpage>271</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.anai.2018.06.020</pub-id><pub-id pub-id-type="pmid">29964225</pub-id></mixed-citation></ref><ref id="CIT0021"><label>21.</label><mixed-citation publication-type="journal"><string-name><surname>Loveless</surname>
<given-names>MH</given-names></string-name>, <string-name><surname>Nall</surname>
<given-names>TM</given-names></string-name>. <article-title>Use of polistes venom in petrolatum: arlacel repositories to immunize against yellow jacket wasp-sting allergy</article-title>. <source><italic toggle="yes">J Immunol</italic></source>. <year>1965</year>;<volume>94</volume>(<issue>5</issue>):<fpage>785</fpage>&#x02013;<lpage>793</lpage>.<pub-id pub-id-type="pmid">14296300</pub-id></mixed-citation></ref><ref id="CIT0022"><label>22.</label><mixed-citation publication-type="journal"><string-name><surname>Poulsen</surname>
<given-names>LK</given-names></string-name>, <string-name><surname>Hummelshoj</surname>
<given-names>L</given-names></string-name>. <article-title>Triggers of IgE class switching and allergy development</article-title>. <source><italic toggle="yes">Ann Med</italic></source>. <year>2007</year>;<volume>39</volume>(<issue>6</issue>):<fpage>440</fpage>&#x02013;<lpage>456</lpage>. doi:<pub-id pub-id-type="doi">10.1080/07853890701449354</pub-id><pub-id pub-id-type="pmid">17852040</pub-id></mixed-citation></ref><ref id="CIT0023"><label>23.</label><mixed-citation publication-type="journal"><string-name><surname>Galli</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>Tsai</surname>
<given-names>M</given-names></string-name>. <article-title>IgE and mast cells in allergic disease</article-title>. <source><italic toggle="yes">Nat Med</italic></source>. <year>2012</year>;<volume>18</volume>(<issue>5</issue>):<fpage>693</fpage>&#x02013;<lpage>704</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nm.2755</pub-id><pub-id pub-id-type="pmid">22561833</pub-id></mixed-citation></ref><ref id="CIT0024"><label>24.</label><mixed-citation publication-type="journal"><string-name><surname>Bradding</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Walls</surname>
<given-names>AF</given-names></string-name>, <string-name><surname>Holgate</surname>
<given-names>ST</given-names></string-name>. <article-title>The role of the mast cell in the pathophysiology of asthma</article-title>. <source><italic toggle="yes">J Allergy Clin Immunol</italic></source>. <year>2006</year>;<volume>117</volume>(<issue>6</issue>):<fpage>1277</fpage>&#x02013;<lpage>1284</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jaci.2006.02.039</pub-id><pub-id pub-id-type="pmid">16750987</pub-id></mixed-citation></ref><ref id="CIT0025"><label>25.</label><mixed-citation publication-type="journal"><string-name><surname>Simons</surname>
<given-names>FE</given-names></string-name>. <article-title>Anaphylaxis</article-title>. <source><italic toggle="yes">J Allergy Clin Immunol</italic></source>. <year>2010</year>;<volume>125</volume>(<issue>2 Suppl 2</issue>):<fpage>S161</fpage>&#x02013;<lpage>181</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jaci.2009.12.981</pub-id><pub-id pub-id-type="pmid">20176258</pub-id></mixed-citation></ref><ref id="CIT0026"><label>26.</label><mixed-citation publication-type="journal"><string-name><surname>Kalesnikoff</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Galli</surname>
<given-names>SJ</given-names></string-name>. <article-title>New developments in mast cell biology</article-title>. <source><italic toggle="yes">Nat Immunol</italic></source>. <year>2008</year>;<volume>9</volume>(<issue>11</issue>):<fpage>1215</fpage>&#x02013;<lpage>1223</lpage>. doi:<pub-id pub-id-type="doi">10.1038/ni.f.216</pub-id><pub-id pub-id-type="pmid">18936782</pub-id></mixed-citation></ref><ref id="CIT0027"><label>27.</label><mixed-citation publication-type="journal"><string-name><surname>Akdis</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Akdis</surname>
<given-names>CA</given-names></string-name>. <article-title>Mechanisms of allergen-specific immunotherapy</article-title>. <source><italic toggle="yes">J Allergy Clin Immunol</italic></source>. <year>2007</year>;<volume>119</volume>(<issue>4</issue>):<fpage>780</fpage>&#x02013;<lpage>791</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jaci.2007.01.022</pub-id><pub-id pub-id-type="pmid">17321578</pub-id></mixed-citation></ref><ref id="CIT0028"><label>28.</label><mixed-citation publication-type="journal"><string-name><surname>Eberlein-Konig</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Ullmann</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Thomas</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Przybilla</surname>
<given-names>B</given-names></string-name>. <article-title>Tryptase and histamine release due to a sting challenge in bee venom allergic patients treated successfully or unsuccessfully with hyposensitization</article-title>. <source><italic toggle="yes">Clin Exp Allergy</italic></source>. <year>1995</year>;<volume>25</volume>(<issue>8</issue>):<fpage>704</fpage>&#x02013;<lpage>712</lpage>. doi:<pub-id pub-id-type="doi">10.1111/cea.1995.25.issue-8</pub-id><pub-id pub-id-type="pmid">7584681</pub-id></mixed-citation></ref><ref id="CIT0029"><label>29.</label><mixed-citation publication-type="journal"><string-name><surname>Jutel</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Muller</surname>
<given-names>UR</given-names></string-name>, <string-name><surname>Fricker</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Rihs</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Pichler</surname>
<given-names>WJ</given-names></string-name>, <string-name><surname>Dahinden</surname>
<given-names>C</given-names></string-name>. <article-title>Influence of bee venom immunotherapy on degranulation and leukotriene generation in human blood basophils</article-title>. <source><italic toggle="yes">Clin Exp Allergy</italic></source>. <year>1996</year>;<volume>26</volume>(<issue>10</issue>):<fpage>1112</fpage>&#x02013;<lpage>1118</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1365-2222.1996.tb00496.x</pub-id><pub-id pub-id-type="pmid">8911695</pub-id></mixed-citation></ref><ref id="CIT0030"><label>30.</label><mixed-citation publication-type="journal"><string-name><surname>Celesnik Smodis</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Silar</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Erzen</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Rijavec</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Kosnik</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Korosec</surname>
<given-names>P</given-names></string-name>. <article-title>Down-regulation of FcepsilonRI-mediated CD63 basophil response during short-term VIT determined venom-nonspecific desensitization</article-title>. <source><italic toggle="yes">PLoS One</italic></source>. <year>2014</year>;<volume>9</volume>(<issue>4</issue>):<fpage>e94762</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0094762</pub-id><pub-id pub-id-type="pmid">24733549</pub-id></mixed-citation></ref><ref id="CIT0031"><label>31.</label><mixed-citation publication-type="journal"><string-name><surname>Meiler</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Zumkehr</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Klunker</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Ruckert</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Akdis</surname>
<given-names>CA</given-names></string-name>, <string-name><surname>Akdis</surname>
<given-names>M</given-names></string-name>. <article-title>In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure</article-title>. <source><italic toggle="yes">J Exp Med</italic></source>. <year>2008</year>;<volume>205</volume>(<issue>12</issue>):<fpage>2887</fpage>&#x02013;<lpage>2898</lpage>. doi:<pub-id pub-id-type="doi">10.1084/jem.20080193</pub-id><pub-id pub-id-type="pmid">19001136</pub-id></mixed-citation></ref><ref id="CIT0032"><label>32.</label><mixed-citation publication-type="journal"><string-name><surname>Celesnik</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Vesel</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Rijavec</surname>
<given-names>M</given-names></string-name>, et al. <article-title>Short-term venom immunotherapy induces desensitization of FcepsilonRI-mediated basophil response</article-title>. <source><italic toggle="yes">Allergy</italic></source>. <year>2012</year>;<volume>67</volume>(<issue>12</issue>):<fpage>1594</fpage>&#x02013;<lpage>1600</lpage>. doi:<pub-id pub-id-type="doi">10.1111/all.12044</pub-id><pub-id pub-id-type="pmid">23066930</pub-id></mixed-citation></ref><ref id="CIT0033"><label>33.</label><mixed-citation publication-type="journal"><string-name><surname>Braga</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Quecchia</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Cavallucci</surname>
<given-names>E</given-names></string-name>, et al. <article-title>T regulatory cells in allergy</article-title>. <source><italic toggle="yes">Int J Immunopathol Pharmacol</italic></source>. <year>2011</year>;<volume>24</volume>(<issue>1 Suppl</issue>):<fpage>55S</fpage>&#x02013;<lpage>64S</lpage>.<pub-id pub-id-type="pmid">21329567</pub-id></mixed-citation></ref><ref id="CIT0034"><label>34.</label><mixed-citation publication-type="journal"><string-name><surname>Calzada</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Baos</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Cremades-Jimeno</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Cardaba</surname>
<given-names>B</given-names></string-name>. <article-title>Immunological mechanisms in allergic diseases and allergen tolerance: the role of treg cells</article-title>. <source><italic toggle="yes">J Immunol Res</italic></source>. <year>2018</year>;<volume>2018</volume>:<fpage>6012053</fpage>. doi:<pub-id pub-id-type="doi">10.1155/2018/6012053</pub-id><pub-id pub-id-type="pmid">30013991</pub-id></mixed-citation></ref><ref id="CIT0035"><label>35.</label><mixed-citation publication-type="journal"><string-name><surname>Malisan</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Briere</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Bridon</surname>
<given-names>JM</given-names></string-name>, et al. <article-title>Interleukin-10 induces immunoglobulin G isotype switch recombination in human CD40-activated naive B lymphocytes</article-title>. <source><italic toggle="yes">J Exp Med</italic></source>. <year>1996</year>;<volume>183</volume>(<issue>3</issue>):<fpage>937</fpage>&#x02013;<lpage>947</lpage>. doi:<pub-id pub-id-type="doi">10.1084/jem.183.3.937</pub-id><pub-id pub-id-type="pmid">8642297</pub-id></mixed-citation></ref><ref id="CIT0036"><label>36.</label><mixed-citation publication-type="journal"><string-name><surname>Defrance</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Vanbervliet</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Briere</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Durand</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Rousset</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Banchereau</surname>
<given-names>J</given-names></string-name>. <article-title>Interleukin 10 and transforming growth factor beta cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A</article-title>. <source><italic toggle="yes">J Exp Med</italic></source>. <year>1992</year>;<volume>175</volume>(<issue>3</issue>):<fpage>671</fpage>&#x02013;<lpage>682</lpage>. doi:<pub-id pub-id-type="doi">10.1084/jem.175.3.671</pub-id><pub-id pub-id-type="pmid">1371300</pub-id></mixed-citation></ref><ref id="CIT0037"><label>37.</label><mixed-citation publication-type="journal"><string-name><surname>Burton</surname>
<given-names>OT</given-names></string-name>, <string-name><surname>Logsdon</surname>
<given-names>SL</given-names></string-name>, <string-name><surname>Zhou</surname>
<given-names>JS</given-names></string-name>, et al. <article-title>Oral immunotherapy induces IgG antibodies that act through FcgammaRIIb to suppress IgE-mediated hypersensitivity</article-title>. <source><italic toggle="yes">J Allergy Clin Immunol</italic></source>. <year>2014</year>;<volume>134</volume>(<issue>6</issue>):<fpage>1310</fpage>&#x02013;<lpage>1317 e1316</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jaci.2014.05.042</pub-id><pub-id pub-id-type="pmid">25042981</pub-id></mixed-citation></ref><ref id="CIT0038"><label>38.</label><mixed-citation publication-type="journal"><string-name><surname>Kennedy Norton</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Barnstein</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Brenzovich</surname>
<given-names>J</given-names></string-name>, et al. <article-title>IL-10 suppresses mast cell IgE receptor expression and signaling in vitro and in vivo</article-title>. <source><italic toggle="yes">J Immunol</italic></source>. <year>2008</year>;<volume>180</volume>(<issue>5</issue>):<fpage>2848</fpage>&#x02013;<lpage>2854</lpage>. doi:<pub-id pub-id-type="doi">10.4049/jimmunol.180.5.2848</pub-id><pub-id pub-id-type="pmid">18292506</pub-id></mixed-citation></ref><ref id="CIT0039"><label>39.</label><mixed-citation publication-type="journal"><string-name><surname>Sturm</surname>
<given-names>GJ</given-names></string-name>, <string-name><surname>Varga</surname>
<given-names>EM</given-names></string-name>, <string-name><surname>Roberts</surname>
<given-names>G</given-names></string-name>, et al. <article-title>EAACI guidelines on allergen immunotherapy: hymenoptera venom allergy</article-title>. <source><italic toggle="yes">Allergy</italic></source>. <year>2018</year>;<volume>73</volume>(<issue>4</issue>):<fpage>744</fpage>&#x02013;<lpage>764</lpage>. doi:<pub-id pub-id-type="doi">10.1111/all.13262</pub-id><pub-id pub-id-type="pmid">28748641</pub-id></mixed-citation></ref><ref id="CIT0040"><label>40.</label><mixed-citation publication-type="journal"><string-name><surname>Dhami</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Zaman</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Varga</surname>
<given-names>EM</given-names></string-name>, et al. <article-title>Allergen immunotherapy for insect venom allergy: a systematic review and meta&#x02010;analysis</article-title>. <source><italic toggle="yes">Allergy</italic></source>. <year>2017</year>;<volume>72</volume>(<issue>3</issue>):<fpage>342</fpage>&#x02013;<lpage>365</lpage>. doi:<pub-id pub-id-type="doi">10.1111/all.13077</pub-id><pub-id pub-id-type="pmid">28120424</pub-id></mixed-citation></ref><ref id="CIT0041"><label>41.</label><mixed-citation publication-type="journal"><string-name><surname>Boyle</surname>
<given-names>RJ</given-names></string-name>, <string-name><surname>Elremeli</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Hockenhull</surname>
<given-names>J</given-names></string-name>, et al. <article-title>Venom immunotherapy for preventing allergic reactions to insect stings</article-title>. <source><italic toggle="yes">Cochrane Database Syst Rev</italic></source>. <year>2012</year>; <issue>10</issue>. doi:<pub-id pub-id-type="doi">10.1002/14651858.CD008838.pub2</pub-id></mixed-citation></ref><ref id="CIT0042"><label>42.</label><mixed-citation publication-type="journal"><string-name><surname>Golden</surname>
<given-names>DB</given-names></string-name>, <string-name><surname>Kagey-Sobotka</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Norman</surname>
<given-names>PS</given-names></string-name>, <string-name><surname>Hamilton</surname>
<given-names>RG</given-names></string-name>, <string-name><surname>Lichtenstein</surname>
<given-names>LM</given-names></string-name>. <article-title>Outcomes of allergy to insect stings in children, with and without venom immunotherapy</article-title>. <source><italic toggle="yes">N Engl J Med</italic></source>. <year>2004</year>;<volume>351</volume>(<issue>7</issue>):<fpage>668</fpage>&#x02013;<lpage>674</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa022952</pub-id><pub-id pub-id-type="pmid">15306668</pub-id></mixed-citation></ref><ref id="CIT0043"><label>43.</label><mixed-citation publication-type="journal"><string-name><surname>Hunt</surname>
<given-names>KJ</given-names></string-name>, <string-name><surname>Valentine</surname>
<given-names>MD</given-names></string-name>, <string-name><surname>Sobotka</surname>
<given-names>AK</given-names></string-name>, <string-name><surname>Benton</surname>
<given-names>AW</given-names></string-name>, <string-name><surname>Amodio</surname>
<given-names>FJ</given-names></string-name>, <string-name><surname>Lichtenstein</surname>
<given-names>LM</given-names></string-name>. <article-title>A controlled trial of immunotherapy in insect hypersensitivity</article-title>. <source><italic toggle="yes">N Engl J Med</italic></source>. <year>1978</year>;<volume>299</volume>(<issue>4</issue>):<fpage>157</fpage>&#x02013;<lpage>161</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJM197807272990401</pub-id><pub-id pub-id-type="pmid">78446</pub-id></mixed-citation></ref><ref id="CIT0044"><label>44.</label><mixed-citation publication-type="journal"><string-name><surname>Oude</surname>
<given-names>JE</given-names></string-name>, <string-name><surname>De</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Van</surname>
<given-names>SDH</given-names></string-name>, <string-name><surname>Guyatt</surname>
<given-names>GH</given-names></string-name>, <string-name><surname>Dubois</surname>
<given-names>A</given-names></string-name>. <article-title>Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom</article-title>. <source><italic toggle="yes">J Allergy Clin Immunol</italic></source>. <year>2002</year>;<volume>110</volume>(<issue>1</issue>):<fpage>174</fpage>&#x02013;<lpage>182</lpage>. doi:<pub-id pub-id-type="doi">10.1067/mai.2002.125827</pub-id><pub-id pub-id-type="pmid">12110838</pub-id></mixed-citation></ref><ref id="CIT0045"><label>45.</label><mixed-citation publication-type="journal"><string-name><surname>Oude Elberink</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Van Der Heide</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Guyatt</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Dubois</surname>
<given-names>A</given-names></string-name>. <article-title>Immunotherapy improves health&#x02010;related quality of life of adult patients with dermal reactions following yellow jacket stings</article-title>. <source><italic toggle="yes">Clin Exp Allergy</italic></source>. <year>2009</year>;<volume>39</volume>(<issue>6</issue>):<fpage>883</fpage>&#x02013;<lpage>889</lpage>. doi:<pub-id pub-id-type="doi">10.1111/cea.2009.39.issue-6</pub-id><pub-id pub-id-type="pmid">19364334</pub-id></mixed-citation></ref><ref id="CIT0046"><label>46.</label><mixed-citation publication-type="journal"><string-name><surname>Pucci</surname>
<given-names>S</given-names></string-name>, <string-name><surname>D&#x02019;Al&#x000f2;</surname>
<given-names>S</given-names></string-name>, <string-name><surname>De Pasquale</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Illuminati</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Makri</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Incorvaia</surname>
<given-names>C</given-names></string-name>. <article-title>Risk of anaphylaxis in patients with large local reactions to hymenoptera stings: a retrospective and prospective study</article-title>. <source><italic toggle="yes">Clin Mol Allergy</italic></source>. <year>2015</year>;<volume>13</volume>(<issue>1</issue>):<fpage>21</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12948-015-0030-z</pub-id><pub-id pub-id-type="pmid">26557045</pub-id></mixed-citation></ref><ref id="CIT0047"><label>47.</label><mixed-citation publication-type="journal"><string-name><surname>Sturm</surname>
<given-names>GJ</given-names></string-name>, <string-name><surname>Kranzelbinder</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Schuster</surname>
<given-names>C</given-names></string-name>, et al. <article-title>Sensitization to Hymenoptera venoms is common, but systemic sting reactions are rare</article-title>. <source><italic toggle="yes">J Allergy Clin Immunol</italic></source>. <year>2014</year>;<volume>133</volume>(<issue>6</issue>):<fpage>1635</fpage>&#x02013;<lpage>1643. e1631</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jaci.2013.10.046</pub-id><pub-id pub-id-type="pmid">24365141</pub-id></mixed-citation></ref><ref id="CIT0048"><label>48.</label><mixed-citation publication-type="journal"><string-name><surname>Bil&#x000f2;</surname>
<given-names>MB</given-names></string-name>, <string-name><surname>Martini</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Pravettoni</surname>
<given-names>V</given-names></string-name>, et al. <article-title>Large local reactions to Hymenoptera stings: outcome of re&#x02010;stings in real life</article-title>. <source><italic toggle="yes">Allergy</italic></source>. <year>2019</year>. doi:<pub-id pub-id-type="doi">10.1111/all.13863</pub-id></mixed-citation></ref><ref id="CIT0049"><label>49.</label><mixed-citation publication-type="journal"><string-name><surname>Bil&#x000f2;</surname>
<given-names>MB</given-names></string-name>, <string-name><surname>Ollert</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Blank</surname>
<given-names>S</given-names></string-name>. <article-title>The role of component-resolved diagnosis in Hymenoptera venom allergy</article-title>. <source><italic toggle="yes">Curr Opin Allergy Clin Immunol</italic></source>. <year>2019</year>;<volume>19</volume>(<issue>6</issue>):<fpage>614</fpage>&#x02013;<lpage>622</lpage>. doi:<pub-id pub-id-type="doi">10.1097/ACI.0000000000000574</pub-id><pub-id pub-id-type="pmid">31343438</pub-id></mixed-citation></ref><ref id="CIT0050"><label>50.</label><mixed-citation publication-type="journal"><string-name><surname>Spillner</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Blank</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Jakob</surname>
<given-names>T</given-names></string-name>. <article-title>Hymenoptera allergens: from venom to &#x0201c;venome&#x0201d;</article-title>. <source><italic toggle="yes">Front Immunol</italic></source>. <year>2014</year>;<volume>5</volume>:<fpage>77</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2014.00077</pub-id><pub-id pub-id-type="pmid">24616722</pub-id></mixed-citation></ref><ref id="CIT0051"><label>51.</label><mixed-citation publication-type="journal"><string-name><surname>Cifuentes</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Vosseler</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Blank</surname>
<given-names>S</given-names></string-name>, et al. <article-title>Identification of Hymenoptera venom&#x02013;allergic patients with negative specific IgE to venom extract by using recombinant allergens</article-title>. <source><italic toggle="yes">J Allergy Clin Immunol</italic></source>. <year>2014</year>;<volume>133</volume>(<issue>3</issue>):<fpage>909</fpage>&#x02013;<lpage>910</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jaci.2013.09.047</pub-id><pub-id pub-id-type="pmid">24290287</pub-id></mixed-citation></ref><ref id="CIT0052"><label>52.</label><mixed-citation publication-type="journal"><string-name><surname>Birnbaum</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Charpin</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Vervloet</surname>
<given-names>D</given-names></string-name>. <article-title>Rapid Hymenoptera venom immunotherapy: comparative safety of three protocols</article-title>. <source><italic toggle="yes">Clin Exp Allergy</italic></source>. <year>1993</year>;<volume>23</volume>(<issue>3</issue>):<fpage>226</fpage>&#x02013;<lpage>230</lpage>. doi:<pub-id pub-id-type="doi">10.1111/cea.1993.23.issue-3</pub-id><pub-id pub-id-type="pmid">8472191</pub-id></mixed-citation></ref><ref id="CIT0053"><label>53.</label><mixed-citation publication-type="journal"><string-name><surname>Laurent</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Smiejan</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Bloch&#x02010;Morot</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Herman</surname>
<given-names>D</given-names></string-name>. <article-title>Safety of Hymenoptera venom rush immunotherapy</article-title>. <source><italic toggle="yes">Allergy</italic></source>. <year>1997</year>;<volume>52</volume>(<issue>1</issue>):<fpage>94</fpage>&#x02013;<lpage>96</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1398-9995.1997.tb02551.x</pub-id><pub-id pub-id-type="pmid">9062635</pub-id></mixed-citation></ref><ref id="CIT0054"><label>54.</label><mixed-citation publication-type="journal"><string-name><surname>Sturm</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Kr&#x000e4;nke</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Rudolph</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Aberer</surname>
<given-names>W</given-names></string-name>. <article-title>Rush Hymenoptera venom immunotherapy: a safe and practical protocol for high-risk patients</article-title>. <source><italic toggle="yes">J Allergy Clin Immunol</italic></source>. <year>2002</year>;<volume>110</volume>(<issue>6</issue>):<fpage>928</fpage>&#x02013;<lpage>933</lpage>. doi:<pub-id pub-id-type="doi">10.1067/mai.2002.129124</pub-id><pub-id pub-id-type="pmid">12464961</pub-id></mixed-citation></ref><ref id="CIT0055"><label>55.</label><mixed-citation publication-type="journal"><string-name><surname>Van der Zwan</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Flinterman</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Jankowski</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Kerckhaert</surname>
<given-names>J</given-names></string-name>. <article-title>Hyposensitisation to wasp venom in six hours</article-title>. <source><italic toggle="yes">Br Med J (Clin Res Ed)</italic></source>. <year>1983</year>;<volume>287</volume>(<issue>6402</issue>):<fpage>1329</fpage>&#x02013;<lpage>1331</lpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.287.6402.1329</pub-id></mixed-citation></ref><ref id="CIT0056"><label>56.</label><mixed-citation publication-type="journal"><string-name><surname>Roll</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Hofbauer</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Ballmer-Weber</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Schmid-Grendelmeier</surname>
<given-names>P</given-names></string-name>. <article-title>Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy</article-title>. <source><italic toggle="yes">J Invest Allerg Clin Immunol</italic></source>. <year>2006</year>;<volume>16</volume>(<issue>2</issue>):<fpage>79</fpage>.</mixed-citation></ref><ref id="CIT0057"><label>57.</label><mixed-citation publication-type="journal"><string-name><surname>Malling</surname>
<given-names>HJ</given-names></string-name>, <string-name><surname>Djurup</surname>
<given-names>R</given-names></string-name>, <string-name><surname>S&#x000f8;ndergaard</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Weeke</surname>
<given-names>B</given-names></string-name>. <article-title>Clustered immunotherapy with yellow jacket venom: evaluation of the influence of time interval on in vivo and in vitro parameters</article-title>. <source><italic toggle="yes">Allergy</italic></source>. <year>1985</year>;<volume>40</volume>(<issue>5</issue>):<fpage>373</fpage>&#x02013;<lpage>383</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1398-9995.1985.tb00250.x</pub-id><pub-id pub-id-type="pmid">4037258</pub-id></mixed-citation></ref><ref id="CIT0058"><label>58.</label><mixed-citation publication-type="journal"><string-name><surname>Schuch</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Brockow</surname>
<given-names>K</given-names></string-name>. <article-title>Mastocytosis and anaphylaxis</article-title>. <source><italic toggle="yes">Immunol Allergy Clin</italic></source>. <year>2017</year>;<volume>37</volume>(<issue>1</issue>):<fpage>153</fpage>&#x02013;<lpage>164</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.iac.2016.08.017</pub-id></mixed-citation></ref><ref id="CIT0059"><label>59.</label><mixed-citation publication-type="journal"><string-name><surname>Gonz&#x000e1;lez-de-Olano</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Matito</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Orfao</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Escribano</surname>
<given-names>L</given-names></string-name>. <article-title>Advances in the understanding and clinical management of mastocytosis and clonal mast cell activation syndromes</article-title>. <source><italic toggle="yes">F1000Research</italic></source>. <year>2016</year>;<volume>5</volume>. doi:<pub-id pub-id-type="doi">10.12688/f1000research.9565.1</pub-id></mixed-citation></ref><ref id="CIT0060"><label>60.</label><mixed-citation publication-type="journal"><string-name><surname>Gruzelle</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Ramassamy</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Bulai Lidiveanu</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Didier</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Mailhol</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Guilleminault</surname>
<given-names>L</given-names></string-name>. <article-title>Safety of ultra&#x02010;rush protocols for hymenoptera venom immunotherapy in systemic mastocytosis</article-title>. <source><italic toggle="yes">Allergy</italic></source>. <year>2018</year>;<volume>73</volume>(<issue>11</issue>):<fpage>2260</fpage>&#x02013;<lpage>2263</lpage>. doi:<pub-id pub-id-type="doi">10.1111/all.2018.73.issue-11</pub-id><pub-id pub-id-type="pmid">29984458</pub-id></mixed-citation></ref><ref id="CIT0061"><label>61.</label><mixed-citation publication-type="journal"><string-name><surname>M&#x000fc;ller</surname>
<given-names>U</given-names></string-name>, <string-name><surname>Helbling</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Berchtold</surname>
<given-names>E</given-names></string-name>. <article-title>Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety</article-title>. <source><italic toggle="yes">J Allergy Clin Immunol</italic></source>. <year>1992</year>;<volume>89</volume>(<issue>2</issue>):<fpage>529</fpage>&#x02013;<lpage>535</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0091-6749(92)90319-W</pub-id><pub-id pub-id-type="pmid">1740583</pub-id></mixed-citation></ref><ref id="CIT0062"><label>62.</label><mixed-citation publication-type="journal"><string-name><surname>Rueff</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Vos</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Oude Elberink</surname>
<given-names>J</given-names></string-name>, et al. <article-title>Predictors of clinical effectiveness of Hymenoptera venom immunotherapy</article-title>. <source><italic toggle="yes">Clin Exp Allergy</italic></source>. <year>2014</year>;<volume>44</volume>(<issue>5</issue>):<fpage>736</fpage>&#x02013;<lpage>746</lpage>. doi:<pub-id pub-id-type="doi">10.1111/cea.2014.44.issue-5</pub-id><pub-id pub-id-type="pmid">24447114</pub-id></mixed-citation></ref><ref id="CIT0063"><label>63.</label><mixed-citation publication-type="journal"><string-name><surname>Hoffman</surname>
<given-names>DR</given-names></string-name>, <string-name><surname>Jacobson</surname>
<given-names>RS</given-names></string-name>. <article-title>Allergens in hymenoptera venom XII: how much protein is in a sting</article-title>. <source><italic toggle="yes">Ann Allergy</italic></source>. <year>1984</year>;<volume>52</volume>(<issue>4</issue>):<fpage>276</fpage>&#x02013;<lpage>278</lpage>.<pub-id pub-id-type="pmid">6711914</pub-id></mixed-citation></ref><ref id="CIT0064"><label>64.</label><mixed-citation publication-type="journal"><string-name><surname>Blank</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Seismann</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Michel</surname>
<given-names>Y</given-names></string-name>, et al. <article-title>Api m 10, a genuine A. mellifera venom allergen, is clinically relevant but underrepresented in therapeutic extracts</article-title>. <source><italic toggle="yes">Allergy</italic></source>. <year>2011</year>;<volume>66</volume>(<issue>10</issue>):<fpage>1322</fpage>&#x02013;<lpage>1329</lpage>. doi:<pub-id pub-id-type="doi">10.1111/all.2011.66.issue-10</pub-id><pub-id pub-id-type="pmid">21658068</pub-id></mixed-citation></ref><ref id="CIT0065"><label>65.</label><mixed-citation publication-type="journal"><string-name><surname>Fischer</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Teufel</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Feidt</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Giel</surname>
<given-names>KE</given-names></string-name>, <string-name><surname>Zipfel</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Biedermann</surname>
<given-names>T</given-names></string-name>. <article-title>Tolerated wasp sting challenge improves health-related quality of life in patients allergic to wasp venom</article-title>. <source><italic toggle="yes">J Allergy Clin Immunol</italic></source>. <year>2013</year>;<volume>132</volume>(<issue>2</issue>):<fpage>489</fpage>&#x02013;<lpage>490</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jaci.2013.03.010</pub-id><pub-id pub-id-type="pmid">23639308</pub-id></mixed-citation></ref><ref id="CIT0066"><label>66.</label><mixed-citation publication-type="journal"><string-name><surname>TSICOPOULOS</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Tonnel</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Wallaert</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Ramon</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Joseph</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Capron</surname>
<given-names>A</given-names></string-name>. <article-title>Short&#x02010;term decrease of skin&#x02010;test sensitivity after rush desensitization in Hymenoptera venom hypersensitivity</article-title>. <source><italic toggle="yes">Clin Exp Allergy</italic></source>. <year>1990</year>;<volume>20</volume>(<issue>3</issue>):<fpage>289</fpage>&#x02013;<lpage>294</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1365-2222.1990.tb02686.x</pub-id><pub-id pub-id-type="pmid">2364309</pub-id></mixed-citation></ref><ref id="CIT0067"><label>67.</label><mixed-citation publication-type="journal"><string-name><surname>Lerch</surname>
<given-names>E</given-names></string-name>, <string-name><surname>M&#x000fc;ller</surname>
<given-names>UR</given-names></string-name>. <article-title>Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients</article-title>. <source><italic toggle="yes">J Allergy Clin Immunol</italic></source>. <year>1998</year>;<volume>101</volume>(<issue>5</issue>):<fpage>606</fpage>&#x02013;<lpage>612</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0091-6749(98)70167-8</pub-id><pub-id pub-id-type="pmid">9600496</pub-id></mixed-citation></ref><ref id="CIT0068"><label>68.</label><mixed-citation publication-type="journal"><string-name><surname>Keating</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Kagey-Sobotka</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Hamilton</surname>
<given-names>RG</given-names></string-name>, <string-name><surname>Yunginger</surname>
<given-names>J</given-names></string-name>. <article-title>Clinical and immunologic follow-up of patients who stop venom immunotherapy</article-title>. <source><italic toggle="yes">J Allergy Clin Immunol</italic></source>. <year>1991</year>;<volume>88</volume>(<issue>3</issue>):<fpage>339</fpage>&#x02013;<lpage>348</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0091-6749(91)90095-6</pub-id><pub-id pub-id-type="pmid">1890261</pub-id></mixed-citation></ref><ref id="CIT0069"><label>69.</label><mixed-citation publication-type="journal"><string-name><surname>Goldberg</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Confino&#x02010;Cohen</surname>
<given-names>R</given-names></string-name>. <article-title>Bee venom immunotherapy &#x02013; how early is it effective?</article-title>
<source><italic toggle="yes">Allergy</italic></source>. <year>2010</year>;<volume>65</volume>(<issue>3</issue>):<fpage>391</fpage>&#x02013;<lpage>395</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1398-9995.2009.02198.x</pub-id><pub-id pub-id-type="pmid">19839973</pub-id></mixed-citation></ref><ref id="CIT0070"><label>70.</label><mixed-citation publication-type="journal"><string-name><surname>Goldberg</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Yogev</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Confino-Cohen</surname>
<given-names>R</given-names></string-name>. <article-title>Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective</article-title>. <source><italic toggle="yes">Int Arch Allergy Immunol</italic></source>. <year>2011</year>;<volume>156</volume>(<issue>1</issue>):<fpage>90</fpage>&#x02013;<lpage>98</lpage>. doi:<pub-id pub-id-type="doi">10.1159/000322258</pub-id><pub-id pub-id-type="pmid">21447964</pub-id></mixed-citation></ref><ref id="CIT0071"><label>71.</label><mixed-citation publication-type="journal"><string-name><surname>Bernkopf</surname>
<given-names>K</given-names></string-name>, <string-name><surname>R&#x000f6;nsch</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Spornraft-Ragaller</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Neumeister</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Bauer</surname>
<given-names>A</given-names></string-name>. <article-title>Safety and tolerability during build-up phase of a rush venom immunotherapy</article-title>. <source><italic toggle="yes">Ann Allergy Asthma Immunol</italic></source>. <year>2016</year>;<volume>116</volume>(<issue>4</issue>):<fpage>360</fpage>&#x02013;<lpage>365</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.anai.2016.02.014</pub-id><pub-id pub-id-type="pmid">27055991</pub-id></mixed-citation></ref><ref id="CIT0072"><label>72.</label><mixed-citation publication-type="journal"><string-name><surname>Kalogeromitros</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Makris</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Koti</surname>
<given-names>I</given-names></string-name>, et al. <article-title>A simple 3-day &#x0201c;rush&#x0201d; venom immunotherapy protocol: documentation of safety</article-title>. <source><italic toggle="yes">Allergol Immunopathol (Madr)</italic></source>. <year>2010</year>;<volume>38</volume>(<issue>2</issue>):<fpage>69</fpage>&#x02013;<lpage>73</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.aller.2009.08.002</pub-id><pub-id pub-id-type="pmid">19853357</pub-id></mixed-citation></ref><ref id="CIT0073"><label>73.</label><mixed-citation publication-type="journal"><string-name><surname>Schiavino</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Nucera</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Pollastrini</surname>
<given-names>E</given-names></string-name>, et al. <article-title>Specific ultrarush desensitization in Hymenoptera venom-allergic patients</article-title>. <source><italic toggle="yes">Ann Allergy Asthma Immunol</italic></source>. <year>2004</year>;<volume>92</volume>(<issue>4</issue>):<fpage>409</fpage>&#x02013;<lpage>413</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1081-1206(10)61775-9</pub-id><pub-id pub-id-type="pmid">15104191</pub-id></mixed-citation></ref><ref id="CIT0074"><label>74.</label><mixed-citation publication-type="journal"><string-name><surname>Cosme</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Sp&#x000ed;nola-Santos</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Pereira-Santos</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Pereira-Barbosa</surname>
<given-names>M</given-names></string-name>. <article-title>Venom Immunotherapy: a 20-year experience with an ultra-rush protocol (210-min)</article-title>. <source><italic toggle="yes">Eur Ann Allergy Clin Immunol</italic></source>. <year>2019</year>;<volume>51</volume>(<issue>3</issue>):<fpage>122</fpage>&#x02013;<lpage>128</lpage>. doi:<pub-id pub-id-type="doi">10.23822/EurAnnACI.1764-1489.85</pub-id><pub-id pub-id-type="pmid">30702236</pub-id></mixed-citation></ref><ref id="CIT0075"><label>75.</label><mixed-citation publication-type="journal"><string-name><surname>Birnbaum</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Ramadour</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Magnan</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Vervloet</surname>
<given-names>D</given-names></string-name>. <article-title>Hymenoptera ultra&#x02010;rush venom immunotherapy (210 min): a safety study and risk factors</article-title>. <source><italic toggle="yes">Clin Exp Allergy</italic></source>. <year>2003</year>;<volume>33</volume>(<issue>1</issue>):<fpage>58</fpage>&#x02013;<lpage>64</lpage>. doi:<pub-id pub-id-type="doi">10.1046/j.1365-2222.2003.01564.x</pub-id><pub-id pub-id-type="pmid">12534550</pub-id></mixed-citation></ref><ref id="CIT0076"><label>76.</label><mixed-citation publication-type="journal"><string-name><surname>Mosbech</surname>
<given-names>H</given-names></string-name>, <string-name><surname>M&#x000fc;ller</surname>
<given-names>U</given-names></string-name>, <collab>Behalf Of The Study Group* O</collab>. <article-title>Side&#x02010;effects of insect venom immunotherapy: results from an EAACI multicenter study</article-title>. <source><italic toggle="yes">Allergy</italic></source>. <year>2000</year>;<volume>55</volume>(<issue>11</issue>):<fpage>1005</fpage>&#x02013;<lpage>1010</lpage>. doi:<pub-id pub-id-type="doi">10.1034/j.1398-9995.2000.00587.x</pub-id><pub-id pub-id-type="pmid">11097308</pub-id></mixed-citation></ref><ref id="CIT0077"><label>77.</label><mixed-citation publication-type="journal"><string-name><surname>Bernstein</surname>
<given-names>DI</given-names></string-name>, <string-name><surname>Epstein</surname>
<given-names>T</given-names></string-name>. <article-title>Systemic reactions to subcutaneous allergen immunotherapy</article-title>. <source><italic toggle="yes">Immunol Allergy Clin</italic></source>. <year>2011</year>;<volume>31</volume>(<issue>2</issue>):<fpage>241</fpage>&#x02013;<lpage>249</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.iac.2011.02.007</pub-id></mixed-citation></ref><ref id="CIT0078"><label>78.</label><mixed-citation publication-type="journal"><string-name><surname>Bernstein</surname>
<given-names>DI</given-names></string-name>, <string-name><surname>Wanner</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Borish</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Liss</surname>
<given-names>GM</given-names></string-name>. <article-title>Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001</article-title>. <source><italic toggle="yes">J Allergy Clin Immunol</italic></source>. <year>2004</year>;<volume>113</volume>(<issue>6</issue>):<fpage>1129</fpage>&#x02013;<lpage>1136</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jaci.2004.02.006</pub-id><pub-id pub-id-type="pmid">15208595</pub-id></mixed-citation></ref><ref id="CIT0079"><label>79.</label><mixed-citation publication-type="journal"><string-name><surname>Reid</surname>
<given-names>MJ</given-names></string-name>, <string-name><surname>Lockey</surname>
<given-names>RF</given-names></string-name>, <string-name><surname>Turkeltaub</surname>
<given-names>PC</given-names></string-name>, <string-name><surname>Platts-Mills</surname>
<given-names>TA</given-names></string-name>. <article-title>Survey of fatalities from skin testing and immunotherapy 1985&#x02013;1989</article-title>. <source><italic toggle="yes">J Allergy Clin Immunol</italic></source>. <year>1993</year>;<volume>92</volume>(<issue>1</issue>):<fpage>6</fpage>&#x02013;<lpage>15</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0091-6749(93)90030-J</pub-id><pub-id pub-id-type="pmid">8335856</pub-id></mixed-citation></ref><ref id="CIT0080"><label>80.</label><mixed-citation publication-type="journal"><string-name><surname>Ru&#x000eb;ff</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Przybilla</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Bil&#x000f3;</surname>
<given-names>MB</given-names></string-name>, et al. <article-title>Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase</article-title>. <source><italic toggle="yes">J Allergy Clin Immunol</italic></source>. <year>2010</year>;<volume>126</volume>(<issue>1</issue>):<fpage>105</fpage>&#x02013;<lpage>111. e105</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jaci.2010.04.025</pub-id><pub-id pub-id-type="pmid">20542320</pub-id></mixed-citation></ref><ref id="CIT0081"><label>81.</label><mixed-citation publication-type="journal"><string-name><surname>Patella</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Florio</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Giuliano</surname>
<given-names>A</given-names></string-name>, et al. <article-title>Hymenoptera venom immunotherapy: tolerance and efficacy of an ultrarush protocol versus a rush and a slow conventional protocol</article-title>. <source><italic toggle="yes">J Allergy (Cairo)</italic></source>. <year>2012</year>;<volume>2012</volume>. doi:<pub-id pub-id-type="doi">10.1155/2012/192192</pub-id></mixed-citation></ref><ref id="CIT0082"><label>82.</label><mixed-citation publication-type="journal"><string-name><surname>M&#x000fc;ller</surname>
<given-names>UR</given-names></string-name>, <string-name><surname>Haeberli</surname>
<given-names>G</given-names></string-name>. <article-title>Use of &#x003b2;-blockers during immunotherapy for Hymenoptera venom allergy</article-title>. <source><italic toggle="yes">J Allergy Clin Immunol</italic></source>. <year>2005</year>;<volume>115</volume>(<issue>3</issue>):<fpage>606</fpage>&#x02013;<lpage>610</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jaci.2004.11.012</pub-id><pub-id pub-id-type="pmid">15753911</pub-id></mixed-citation></ref><ref id="CIT0083"><label>83.</label><mixed-citation publication-type="journal"><string-name><surname>Brown</surname>
<given-names>SG</given-names></string-name>. <article-title>Clinical features and severity grading of anaphylaxis</article-title>. <source><italic toggle="yes">J Allergy Clin Immunol</italic></source>. <year>2004</year>;<volume>114</volume>(<issue>2</issue>):<fpage>371</fpage>&#x02013;<lpage>376</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jaci.2004.04.029</pub-id><pub-id pub-id-type="pmid">15316518</pub-id></mixed-citation></ref><ref id="CIT0084"><label>84.</label><mixed-citation publication-type="journal"><string-name><surname>Pitsios</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Demoly</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Bil&#x000f2;</surname>
<given-names>M</given-names></string-name>, et al. <article-title>Clinical contraindications to allergen immunotherapy: an EAACI position paper</article-title>. <source><italic toggle="yes">Allergy</italic></source>. <year>2015</year>;<volume>70</volume>(<issue>8</issue>):<fpage>897</fpage>&#x02013;<lpage>909</lpage>. doi:<pub-id pub-id-type="doi">10.1111/all.2015.70.issue-8</pub-id><pub-id pub-id-type="pmid">25913519</pub-id></mixed-citation></ref><ref id="CIT0085"><label>85.</label><mixed-citation publication-type="journal"><string-name><surname>Stoevesandt</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Hosp</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Kerstan</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Trautmann</surname>
<given-names>A</given-names></string-name>. <article-title>Hymenoptera venom immunotherapy while maintaining cardiovascular medication: safe and effective</article-title>. <source><italic toggle="yes">Ann Allergy Asthma Immunol</italic></source>. <year>2015</year>;<volume>114</volume>(<issue>5</issue>):<fpage>411</fpage>&#x02013;<lpage>416</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.anai.2015.03.001</pub-id><pub-id pub-id-type="pmid">25952636</pub-id></mixed-citation></ref><ref id="CIT0086"><label>86.</label><mixed-citation publication-type="journal"><string-name><surname>Brockow</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Kiehn</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Riethm&#x000fc;llerb</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Vieluf</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Berger</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Ring</surname>
<given-names>J</given-names></string-name>. <article-title>Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: a prospective, randomized, placebo-controlled trial</article-title>. <source><italic toggle="yes">J Allergy Clin Immunol</italic></source>. <year>1997</year>;<volume>100</volume>(<issue>4</issue>):<fpage>458</fpage>&#x02013;<lpage>463</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0091-6749(97)70135-0</pub-id><pub-id pub-id-type="pmid">9338537</pub-id></mixed-citation></ref><ref id="CIT0087"><label>87.</label><mixed-citation publication-type="journal"><string-name><surname>Kontou&#x02010;Fili</surname>
<given-names>K</given-names></string-name>. <article-title>ALLERGY Net: high omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis</article-title>. <source><italic toggle="yes">Allergy</italic></source>. <year>2008</year>;<volume>63</volume>(<issue>3</issue>):<fpage>376</fpage>&#x02013;<lpage>378</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1398-9995.2007.01604.x</pub-id><pub-id pub-id-type="pmid">18269681</pub-id></mixed-citation></ref><ref id="CIT0088"><label>88.</label><mixed-citation publication-type="journal"><string-name><surname>Schulze</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Rose</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Zielen</surname>
<given-names>S</given-names></string-name>. <article-title>Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab</article-title>. <source><italic toggle="yes">Allergy</italic></source>. <year>2007</year>;<volume>62</volume>(<issue>8</issue>):<fpage>963</fpage>&#x02013;<lpage>964</lpage>. doi:<pub-id pub-id-type="doi">10.1111/all.2007.62.issue-8</pub-id><pub-id pub-id-type="pmid">17484729</pub-id></mixed-citation></ref><ref id="CIT0089"><label>89.</label><mixed-citation publication-type="journal"><string-name><surname>Stretz</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Oppel</surname>
<given-names>E</given-names></string-name>, <string-name><surname>R&#x000e4;wer</surname>
<given-names>HC</given-names></string-name>, et al. <article-title>Overcoming severe adverse reactions to venom immunotherapy using anti&#x02010;Ig E antibodies in combination with a high maintenance dose</article-title>. <source><italic toggle="yes">Clin Exp Allergy</italic></source>. <year>2017</year>;<volume>47</volume>(<issue>12</issue>):<fpage>1631</fpage>&#x02013;<lpage>1639</lpage>. doi:<pub-id pub-id-type="doi">10.1111/cea.12997</pub-id><pub-id pub-id-type="pmid">28802075</pub-id></mixed-citation></ref></ref-list></back></article>